Article

Urology has largest 1-year compensation gain

The field of urology experienced the largest increase in compensation for any medical or surgical specialty in the period 1999-2000, according to findings from the American Medical Group Association's 2001 Medical Group Compensation and Productivity Survey. The survey includes salary and productivity data on 93 specialties, 25 other health care provider positions, and 16 administrative positions.

Related Videos
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
Woman typing on laptop | Image Credit: © Gorodenkoff - stock.adobe.com
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Related Content
FDA accepts sNDA for darolutamide plus ADT in mHSPC
November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke
The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC
November 19th 2024

QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC

Hannah Clarke
At the time of data cutoff, 71% of patients achieved a complete response following treatment.
Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT
November 19th 2024

Head-to-head trial to compare 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT

Hannah Clarke
The primary objective is to compare the detection rate of sites of prostate cancer recurrence between the 2 agents.
© 2024 MJH Life Sciences

All rights reserved.